Detalhe da pesquisa
1.
Age-induced changes in anti-tumor immunity alter the tumor immune infiltrate and impact response to immuno-oncology treatments.
Front Immunol
; 14: 1258291, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37920465
2.
BET inhibition targets ABC-DLBCL constitutive B-cell receptor signaling through PAX5.
Blood Adv
; 7(17): 5108-5121, 2023 09 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37184294
3.
Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners.
Mol Cancer Ther
; 22(5): 630-645, 2023 05 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36912782
4.
Systemic nano-delivery of low-dose STING agonist targeted to CD103+ dendritic cells for cancer immunotherapy.
J Control Release
; 345: 721-733, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35378213
5.
PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors.
Oncoimmunology
; 11(1): 2083755, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35756843
6.
Small molecule AZD4635 inhibitor of A2AR signaling rescues immune cell function including CD103+ dendritic cells enhancing anti-tumor immunity.
J Immunother Cancer
; 8(2)2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32727810